Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

  1. Rugo, H.S.
  2. André, F.
  3. Yamashita, T.
  4. Cerda, H.
  5. Toledano, I.
  6. Stemmer, S.M.
  7. Jurado, J.C.
  8. Juric, D.
  9. Mayer, I.
  10. Ciruelos, E.M.
  11. Iwata, H.
  12. Conte, P.
  13. Campone, M.
  14. Wilke, C.
  15. Mills, D.
  16. Lteif, A.
  17. Miller, M.
  18. Gaudenzi, F.
  19. Loibl, S.
Revista:
Annals of Oncology

ISSN: 1569-8041,  0923-7534

Ano de publicación: 2020

Volume: 31

Número: 8

Páxinas: 1001-1010

Tipo: Artigo

DOI: 10.1016/J.ANNONC.2020.05.001 GOOGLE SCHOLAR lock_openAcceso aberto editor
Fonte de datos: Scopus